6F0H

Crystal structure ASF1-ip4

• PDB DOI:  https://doi.org/10.2210/pdb6F0H/pdb

• Classification: CHAPERONE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2017-11-20 Released: 2019-06-12 
• Deposition Author(s): Bakail, M., Richet, N., Le Du, M.H., Andreani, J., Guerois, R., Ochsenbein, F.
• Funding Organization(s): French National Research Agency

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.98 Å
• R-Value Free: 0.242 
• R-Value Work: 0.196 
• R-Value Observed: 0.198 

Literature

Design on a Rational Basis of High-Affinity Peptides Inhibiting the Histone Chaperone ASF1.

Bakail, M., Gaubert, A., Andreani, J., Moal, G., Pinna, G., Boyarchuk, E., Gaillard, M.C., Courbeyrette, R., Mann, C., Thuret, J.Y., Guichard, B., Murciano, B., Richet, N., Poitou, A., Frederic, C., Le Du, M.H., Agez, M., Roelants, C., Gurard-Levin, Z.A., Almouzni, G., Cherradi, N., Guerois, R., Ochsenbein, F.

(2019) Cell Chem Biol 26: 1573-1585.e10

• PubMed: 31543461 
• DOI: https://doi.org/10.1016/j.chembiol.2019.09.002
• Primary Citation of Related Structures:  
  6F0F, 6F0G, 6F0H


• PubMed Abstract: 
  

Anti-silencing function 1 (ASF1) is a conserved H3-H4 histone chaperone involved in histone dynamics during replication, transcription, and DNA repair. Overexpressed in proliferating tissues including many tumors, ASF1 has emerged as a promising therapeutic target. Here, we combine structural, computational, and biochemical approaches to design peptides that inhibit the ASF1-histone interaction. Starting from the structure of the human ASF1-histone complex, we developed a rational design strategy combining epitope tethering and optimization of interface contacts to identify a potent peptide inhibitor with a dissociation constant of 3 nM. When introduced into cultured cells, the inhibitors impair cell proliferation, perturb cell-cycle progression, and reduce cell migration and invasion in a manner commensurate with their affinity for ASF1. Finally, we find that direct injection of the most potent ASF1 peptide inhibitor in mouse allografts reduces tumor growth. Our results open new avenues to use ASF1 inhibitors as promising leads for cancer therapy.

---

Organizational Affiliation: 

Institute Joliot, Commissariat à l'énergie Atomique (CEA), Direction de la Recherche Fondamentale (DRF), 91191 Gif-sur-Yvette, France; Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 91198 Gif-sur-Yvette Cedex, France. Electronic address: [e-mail].

Biological Assembly 1  

Global Symmetry: Cyclic - C6  (3D View)
Global Stoichiometry: Hetero 12-mer - A6B6 

Biological assembly 1 generated by PISA (software)

Biological Assembly Evidence: isothermal titration calorimetry

Macromolecule Content

• Total Structure Weight: 42 kDa 
• Atom Count: 3,241 
• Modelled Residue Count: 356 
• Deposited Residue Count: 368 
• Unique protein chains: 2

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Histone chaperone ASF1A	A, C	158	Homo sapiens	Mutation(s): 0  Gene Names: ASF1A, CGI-98, HSPC146
UniProt & NIH Common Fund Data Resources
Find proteins for Q9Y294 (Homo sapiens) Explore Q9Y294  Go to UniProtKB:  Q9Y294
PHAROS:  Q9Y294

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
ip4	B, D	26	Homo sapiens	Mutation(s): 0

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
CIT	J [auth C]	CITRIC ACID C6 H8 O7 KRKNYBCHXYNGOX-UHFFFAOYSA-N
SO4	E [auth A], F [auth A], H [auth B], K [auth D]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
GOL	G [auth A], I [auth C]	GLYCEROL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.98 Å
• R-Value Free: 0.242 
• R-Value Work: 0.196 
• R-Value Observed: 0.198 
• Space Group: P 6₃ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 73.44	α = 90
b = 73.44	β = 90
c = 229.02	γ = 120

Software Package:

Software Name	Purpose
BUSTER	refinement
XDS	data reduction
XDS	data scaling
MOLREP	phasing

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2019-06-12 
Deposition Author(s): Bakail, M., Richet, N., Le Du, M.H., Andreani, J., Guerois, R., Ochsenbein, F.

---

Funding Organization	Location	Grant Number
French National Research Agency	France	CHAPINHIB
French National Research Agency	France	FRISBI
French National Research Agency	France	BIPBIP

Revision History  

• Version 1.0: 2019-06-12
  Type: Initial release
  
• Version 1.1: 2020-01-01
  Changes: Database references